The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical Benefits Scheme (PBS).
Read More
Study: Third of nAMD patients safely stopped eye injections
A new study has shown up to a third of neovascular age-related macular degeneration (nAMD) patients may safely be able to stop intravitreal injections after a year, while also highlighting a potential biomarker to identify the best candidates.
Read More
Read More
Artificial intelligence: eyecare’s friend of foe?
Eyetelligence is a new Australian-developed AI system helping clinicians screen for three types of eye disease. PROFESSOR MING HE – the clinical expert behind the software – discusses why optometrists should embrace the technology and its potential in other health fields.
Read More
Annual out-of-pocket eye injection costs to double to $3,900 under rebate cut – modelling
Prominent Australian Ms Ita Buttrose has used a National Press Club address to reveal alarming new data showing that 47,000 more Australians will experience severe vision loss or blindness if a Medicare rebate cut for intravitreal injections is given the green light.
Read More
Read More
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment.
Read More
Read More
Australia trial commences for ‘game-changer’ retinal disease eye drop
A clinical trial is under way in Australia for a novel eye drop treatment for retinal vascular diseases that could replace the current approach involving serial intravitreal injections into the back of the eye.
Read More
Read More
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME).
Read More
Read More
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel treatment for neovascular age-related macular degeneration (nAMD).
Read More
Read More
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema (DME).
Read More
Read More
Telehealth to continue gathering pace post-pandemic
Rapid uptake of telehealth services amid the COVID-19 pandemic is energising research focused on new ways to remotely diagnose and monitor eye disease, according to one of Australia’s top-ranked eye research institutes.
Read More
Read More